Last reviewed · How we verify
NCT07182435
Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid Tumors
EARLY_PHASE1 trial testing personalized neoantigen mRNA tumor vaccine in Solid Tumor Malignancies in 36 participants. Not yet recruiting.
31 December 2028
Quick facts
| Lead sponsor | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 15 September 2025 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- personalized neoantigen mRNA tumor vaccine — full drug profile →
Conditions studied
- Solid Tumor Malignancies — all drugs for Solid Tumor Malignancies →
Sponsor
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Who can join
Adults 18 to 70, any sex, with Solid Tumor Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1 clinical study investigating RH125 as monotherapy or in combination therapy in patients with locally advanced or metastatic solid tumors who failed standard treatment, or were intolerant to standard treatment, or declined standard treatment. The aim of the study is to evaluate the tolerability, safety, immunogenicity, and preliminary efficacy of RH125 monotherapy or combination with PD-1 blocker.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The evolution of vaccine strategies for colorectal cancer: from conventional approaches to the mRNA era.
Wang T, Mei Y, Liu S, Wang H, et al · · 2026 · PMID 42183284 · DOI 10.3389/fimmu.2026.1778522
Verify or expand the search:
- PubMed search for NCT07182435
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor Malignancies
Currently open trials in the same condition.
- NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
- NCT07231120 — A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy · Phase 1 · recruiting
- NCT07167381 — xDRIVE for Florida-based Cancer Patients · NA · recruiting
- NCT07174453 — Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies · Phase 3 · recruiting
- NCT07181473 — A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors · Phase 1 · recruiting
Other Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center trials
Trials by the same sponsor.
- NCT07040228 — A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Tr · Phase 1, PHASE2 · recruiting
- NCT06776770 — A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer · Phase 1, PHASE2 · recruiting
- NCT06776757 — Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colore · Phase 1, PHASE2 · recruiting
- NCT07026825 — Surgical Resection Enhances Survival in Gastric-type Endocervical Adenocarcinoma: A SEER-Based Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07182435 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
- Last refreshed: 19 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07182435.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing